Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.

MLA

Howard, James F., Jr, et al. “Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.” Expert Opinion on Investigational Drugs, vol. 30, no. 5, May 2021, pp. 483–93. EBSCOhost, https://doi.org/10.1080/13543784.2021.1897567.

APA

Howard, J. F., Jr, Vissing, J., Gilhus, N. E., Leite, M. I., Utsugisawa, K., Duda, P. W., Farzaneh-Far, R., Murai, H., & Wiendl, H. (2021). Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis. Expert Opinion on Investigational Drugs, 30(5), 483–493. https://doi.org/10.1080/13543784.2021.1897567

Chicago

Howard, James F, Jr, John Vissing, Nils E Gilhus, M Isabel Leite, Kimiaki Utsugisawa, Petra W Duda, Ramin Farzaneh-Far, Hiroyuki Murai, and Heinz Wiendl. 2021. “Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.” Expert Opinion on Investigational Drugs 30 (5): 483–93. doi:10.1080/13543784.2021.1897567.